F-Tryptophan PET/CT in Human Cancers

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Barbara Ann Karmanos Cancer Institute
Study ID
NCT05556473
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 1-(2-[18F]FLUOROETHYL)-L-Tryptophan — DRUG
    Radioactive tracer 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan 0.14mCi/kg/5MBq/kg injection given one time prior to PET Scan.

Study Details

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

Key Dates

Start date
Sep 29, 2022
Status verified
Jan 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: [18F]FETrp PET radiotracer
    All participants will receive the tracer to evaluate the uptake of \[18F\]FETrp PET/CT on intra- and extracranial cancers.

Primary Outcome Measure

The percent difference in tracer uptake values between the tumor mass and the background (non-tumor tissue) [ Time Frame: During procedure (from right after tracer injection to 1-hour post-injection) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Karmanos Cancer InstituteDetroitMichigan48201
Csaba Juhasz, MD, PhD
[email protected]
313-966-5136

Find similar trials in Detroit, MI

By condition
Breast cancerNeuroendocrine tumorsColorectal cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncology
By research site
Karmanos Cancer Institute· Detroit, MI

Related Studies